Celldex Therapeutics
CLDX
CLDX
158 hedge funds and large institutions have $1.35B invested in Celldex Therapeutics in 2022 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 58 increasing their positions, 38 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
1% more funds holding
Funds holding: 156 → 158 (+2)
8% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 24
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Holders
158
Holding in Top 10
4
Calls
$21.5M
Puts
$10.1M
Top Buyers
| 1 | +$39.1M | |
| 2 | +$26.8M | |
| 3 | +$24.6M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$19.4M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$14.3M |
Top Sellers
| 1 | -$63M | |
| 2 | -$24.2M | |
| 3 | -$11M | |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.8M |
| 5 |
Morgan Stanley
New York
|
-$8.54M |